Compare VRRM & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRRM | MESO |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2016 | N/A |
| Metric | VRRM | MESO |
|---|---|---|
| Price | $16.59 | $14.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $26.90 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 199.0K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 347.37 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $132,969,000.00 | N/A |
| Revenue This Year | $6.63 | $633.98 |
| Revenue Next Year | $7.66 | $29.51 |
| P/E Ratio | $19.76 | ★ N/A |
| Revenue Growth | ★ 14.61 | N/A |
| 52 Week Low | $15.58 | $9.61 |
| 52 Week High | $25.83 | $21.50 |
| Indicator | VRRM | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 30.25 | 30.02 |
| Support Level | N/A | $10.14 |
| Resistance Level | $25.18 | $16.32 |
| Average True Range (ATR) | 0.63 | 0.50 |
| MACD | -0.08 | -0.24 |
| Stochastic Oscillator | 28.09 | 15.60 |
Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe, and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three reportable segments: Commercial Services, Government Solutions, and Parking Solutions. Maximum revenue is generated from the Commercial Services segment, which offers toll and violation management solutions and title and registration services for commercial fleet customers, including RACs and FMCs in North America. In Europe, it provides tolling and violations processing services.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.